Pomegra
Cambridge synthetic biology spinout Houdini Bio secures £1.5M in an oversubscribed pre-seed round to deploy AI-driven anti-silencing technology across gene and cell therapy pipelines.
- Houdini Bio raised £1.5M led by SCVC, with participation from Deep Science Ventures and Cambridge Enterprise VC.
- The company's technology increases therapeutic gene expression by more than 10x versus competing approaches.
- The University of Cambridge spinout emerged from stealth in June 2026, having hit projected milestones in one-third of the expected time.
Lead
Houdini Bio, a computational synthetic biology company spun out of the University of Cambridge, has closed a £1.5 million ($1.9 million) oversubscribed pre-seed funding round, emerging from stealth in June 2026. The round was led by SCVC, the venture arm of Science Creates, with co-investment from Deep Science Ventures and Cambridge Enterprise. The raise, which combines equity with non-dilutive grant funding, will accelerate team growth and co-development partnerships with pharmaceutical companies seeking to improve the durability of next-generation therapies.What Happened
HoudiniBio was founded in 2025 to address one of gene therapy's most persistent clinical and commercial obstacles: transgene silencing, a process by which a patient's own cells deactivate introduced therapeutic DNA over time. This degradation of efficacy undermines treatments that require sustained gene expression and inflates the development cost of therapies already burdened by complex manufacturing processes.The company's platform applies first-principles biology combined with machine learning to redesign therapeutic DNA sequences. By altering the genetic architecture without changing the underlying therapeutic function, Houdini Bio's approach prevents host cells from switching off the introduced payload. Independent validation shows the technology delivers more than a tenfold improvement in gene expression relative to conventional sequences.
Academic co-founder Prof. Paul Lehner anchors the scientific foundation of the platform. The investor board includes Harry Destecroix MBE as Investor Director and Kerstin Papenfuss, reflecting backing from investors with deep expertise in translating early-stage science into commercial assets.
Strategic Context
The anti-silencing approach is designed to be payload- and delivery-system agnostic, meaning it can integrate into existing gene therapy and cell therapy pipelines without requiring partners to overhaul their core technology. This positions HoudiniBio as an enabling layer for a broad range of pharmaceutical developers, from established players with late-stage programs to DeepTech innovators building next-generation drug platforms.
The company's milestone execution record — achieving projected technical targets in one-third of the originally projected timeframe — has been central to investor confidence at a stage where clinical proof of concept remains ahead.
Market Context
The funding arrives during a measured recovery in UK biotech financing. After a difficult 2025, in which domestic venture investment fell 13.2% year-on-year to £1.79 billion, Q1 2026 showed renewed momentum with total equity financing reaching £552 million, up 17% from the prior quarter. Seed and pre-seed activity has remained comparatively resilient, supported by university venture arms and sector-specialist funds targeting foundational platform technologies in life sciences.
Gene and cell therapy continues to attract institutional focus globally despite high development costs, given the potential for curative outcomes in disease areas with unmet need. Technologies that extend efficacy or reduce failure rates at the payload level carry significant leverage across a pipeline.
